Slide 1: Third Quarter 2016 Results
Exhibit 99.2 K Pharm Third Quarter 2016 Results
Slide 2: Forward Looking Statement
Forward Looking Statement This presentation contains forward-looking statements, including statements about our plans to develop and commercialize our product candidates, our planned clinical trials for our prodrug product candidates, the timing of and our ability to obtain and maintain regulatory a
Slide 3: Third Quarter 2016 — Conference Call Participants
Third Quarter 2016 — Conference Call Participants Presenters * Travis Mickle, Ph.D. - President & Chief Executive Officer * Dan Cohen—- EVP, Government & Public Relations « R. LaDuane Clifton — Chief Financial Officer
Slide 4: KemPharm Overview
KemPharm Overview + Specialty pharmaceutical company discovering and developing novel prodrugs + Building a pipeline of product candidates for ADHD, pain and CNS disorders + Leveraging our LAT Platform Technology to improve the attributes of approved drugsin large markets aa 6”. a@D- ae Approved Dru
Slide 5: Third Quarter 2016 & Recent Updates
Third Quarter 2016 & Recent Updates Clinical & Regulatory Corporate & Financial + Prioritized KP415 and KP201/IR as + Net loss of $0.92 per basic and diluted Co-Lead Product Candidates share for the quarter ended 9/30/2016 + Received Clearance from FDA to + Total cash was $92.0 million at Initiate C
Slide 6: KP415 Product Overview
KP415 Product Overview + Extended release prodrug of methylphenidate + Preclinical data: Tmax approximately three times longer than IR methylphenidate + May offer more consistent drug delivery + Methylphenidate accounted for approximately 19.7 million TRx’s and $4.2 billion in sales in 2015* + Brand
Slide 7: KP201/IR (APAP-free)
KP201/IR (APAP-free) Product Overview Development Timeline + IR formulation of benzhydrocodone v¥ Completed KP201/IR EOP1 in an aversive formulation Potentially the first IR hydrocodone- related product without APAP in the U.S. KP201 Intranasal PK Trial (A03) already completed (n=51): o Significantl
Slide 8: KP511/ER
KP511/ER Product Overview + ER formulation of KP511, a prodrug of hydromorphone + Demonstrated comparable hydromorphone exposure vs. equimolar dose of Dilaudid™ in oral human proof-of-concept trial + Limited oral bioavailability at high doses (potential overdose protection) Development Timeline v Po
Slide 9: Formal Dispute Resolution Request (FDRR) Update
Formal Dispute Resolution Request (FDRR) Update *« KemPharm filed an appeal of the CRL for Apadaz™ through the initiation of the FDRR process (announced on Nov. 3, 2016) + FDRR process is designed to provide pathway by which applicants seek to resolve scientific and/or medical policy disputes that c
Slide 10: Q3 2016 Financial Update
Q3 2016 Financial Update * Total cash of $92.0M as of 9/30/2016, a decrease of $10.6M vs. 6/30/2016 (includes cash, cash equivalents, restricted cash, marketable securities and long-term investments) + Q3 2016 net loss of ($13.4M), or ($0.92) per basic and diluted share, and vs. Q3 2015 net loss of
Slide 11: KemPharm Expected Milestones
KemPharm Expected Milestones 2016 2017 2018 2019 —_ OO Product KP415 KP415 KP201/IR KP511 (API) KP415 KP415 KP201/IR KP511/ER Eve Human POC Data Initiate Pivotal Efficacy Trial Human Clinical Trial Initiation & Intranasal HAL Study Data Intranasal PK and HAL Study Data Pivotal Efficacy Trial Results
Slide 12: Third Quarter 2016 Results
K Pharm Third Quarter 2016 Results